Intravenous bevacizumab as a novel treatment for refractory left ventricular assist device-related gastrointestinal bleeding

J Heart Lung Transplant. 2020 May;39(5):492-495. doi: 10.1016/j.healun.2020.02.012. Epub 2020 Feb 24.

Authors

Rabea Asleh¹, Hasan Ahmad Hasan Albitar², Sarah D Schettle¹, Sudhir S Kushwaha¹, Naveen L Pereira¹, Atta Behfar¹, John M Stulak³, Richard J Rodeheffer¹, Vivek N Iyer⁴

Affiliations

¹ Departments of Cardiovascular Diseases.
² Internal Medicine.
³ Division of Cardiovascular Surgery.
⁴ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: iyer.vivek@mayo.edu.

PMID: 32173217
DOI: 10.1016/j.healun.2020.02.012

No abstract available

Publication types

Letter

MeSH terms

Administration, Intravenous
Aged
Angiogenesis Inhibitors / administration & dosage
Bevacizumab / administration & dosage*
Female
Follow-Up Studies
Gastrointestinal Hemorrhage / drug therapy*
Gastrointestinal Hemorrhage / etiology
Heart Failure / therapy*
Heart-Assist Devices / adverse effects*
Humans
Male
Retrospective Studies
Treatment Outcome

Substances

Angiogenesis Inhibitors
Bevacizumab